Company Financials

Halozyme Therapeutics, Inc. Financials

United States dollar

business Halozyme Therapeutics, Inc. Company Profile

Main Stock Listing

NASDAQ: HALO

Market Capitalization $8.27 Billion as of Jan. 1, 2026

Market Cap History

Valuations Metrics as of Jan. 3, 2026

Trailing PE 14.83
Forward PE 8.65
Price to Sales TTM $6.65
Price to Book MRQ $16.40
Enterprise to Revenue 7.33
Enterprise to EBITDA 11.20

Financial Reports as of Sep. 30, 2025

Financials

Fiscal Year Ends 2024-12-31
Most Recent Quarter 2025-09-30
Profit Margin 47.91%
Operating Margin 61.51%
Return on Assets TTM 21.24%
Return on Equity TTM 124.50%

Income Statement

Revenue TTM $1,242,851,968
Revenue per Share TTM $10.19
Quarterly Revenue Growth 22.10%
Gross Profit TTM $980,758,976
EBITDA $819,184,000
Net Income to Common TTM $595,491,968
Diluted EPS TTM $4.74
Quarterly Earnings Growth YoY 27.90%

Balance Sheet

Total Cash MRQ $701,963,008
Total Cash per Share MRQ $5.97
Total Debt MRQ $
Total Debt to Equity MRQ 305.38
Current Ratio MRQ 1.59
Book Value per Share MRQ $4.29

Cash Flow

Operating Cash Flow TTM $610,995,968
Levered Free Cash Flow TTM $428,435,872

HALO Stock Info as of Jan. 3, 2026

Stock Statistics

Shares Outstanding 117,523,000
Float Shares 116,203,476
Avg 10 Volume 1,383,620
Avg 30 Volume None
Shares Short 12,500,858
Short Ratio 4.97
Short % of Shares 14.81%
% Held by Insiders 1.14%
% Held by Institutions 105.85%

Stock Price Summary

Beta 0.95
Fifty Two Week Low $47.50
Fifty Two Week High $79.50
Fifty Two Week Change 28.16%
Day 50 MA $67.27
Day 200 MA $63.63

Dividends and Splits

Forward Annual Dividend Rate $
Forward Annual Dividend Yield %
Trailing Annual Dividend Rate $0.00
Trailing Annual Dividend Yield 0.00%
Payout Ratio 0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date